Results 71 to 80 of about 29,485 (291)

The emergence of bispecific antibodies as novel cancer therapeutics [PDF]

, 2023
Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new
Li, Robert
core  

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy

Molecular Therapy: Methods & Clinical Development, 2017
Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse, Thomas Shum, Xavier Legras, Mercedes Barzi, Frank P. Pankowicz, Stephen Gottschalk, Karl-Dimiter Bissig   +6 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐07261271 in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim There is an unmet need for more effective therapies in inflammatory bowel disease (IBD). A single drug that blocks multiple distinct pathogenic pathways may offer therapeutic benefit superior to current monotherapies. PF‐07261271, a bispecific antibody targeting both the p40 subunit of interleukin‐12/23 and tumour necrosis factor‐like cytokine 1A ...
Srividya Neelakantan, Christopher Banfield, Kenneth Hung, Anna Sapone, Vivek Pradhan, Yuxi Zhao, Dana Parsons‐Rich, Grace Lee, Bryce G. Johnson, Elena Peeva, Michael S. Vincent, Valerie M. Clerin   +11 more
wiley   +1 more source

Bispecific Antibodies in Clinical Practice and Clinical Trials (Literature Review) [PDF]

, 2019
Therapeutic monoclonal antibodies have long been an effective tool deployed by physicians of different specialties, particularly by oncologists. Bispecific antibodies opened up new horizons in the treatment of cancer as they allow to involve a patient’s ...
O.N. Solopova, Vsevolod Andreevich Misyurin, O. N. Solopova   +2 more
core   +1 more source

Bispecific antibodies come to the aid of cancer immunotherapy

, 2021
Three collaborative studies published by the groups of Vogelstein, Gabelli, and Zhou report the development of specially designed bispecific antibodies that may help in overcoming the limitations of current immunotherapies. The bispecific antibodies have
Levine, Arnold J., Gerry Melino, Amelio, Ivano, Arnold J. Levine, Ivano Amelio, Melino, Gerry   +5 more
core   +1 more source

Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies

Biopharmaceutics &Drug Disposition, EarlyView.
This study identified new optimal allometric scaling exponents for human PK prediction of monoclonal antibodies with linear PKs from marmoset PK data. In addition, immunogenicity in common marmosets was evaluated following the repeated dose of golimumab and ustekinumab, minimal anti‐drug antibodies were detected.
Ayaka Tajiri, Shogo Matsumoto, Nanami Furukawa, Kensuke Kagiyama, Hiroshi Ikeda, Kazumasa Fukasawa, Hiroki Takano   +6 more
wiley   +1 more source